Integrin Receptor Antagonist [EPC]

229957 reported adverse events

Drugs of this class: NATALIZUMAB VEDOLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Integrin Receptor Antagonist [EPC] class:

# Side effect Count
0 FATIGUE 22599
1 OFF LABEL USE 16958
2 MULTIPLE SCLEROSIS RELAPSE 16106
3 DRUG INEFFECTIVE 12952
4 HEADACHE 12052
5 COLITIS ULCERATIVE 9554
6 GAIT DISTURBANCE 9553
7 MALAISE 9295
8 MULTIPLE SCLEROSIS 9214
9 ASTHENIA 9147
See all common reactions for Integrin Receptor Antagonist [EPC]

Drugs of the Integrin Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 THERAPEUTIC REACTION TIME DECREASED 1780 0.9204
1 JC VIRUS TEST POSITIVE 383 0.4522
2 LOSS OF THERAPEUTIC RESPONSE 616 0.4366
3 AGRAPHIA 192 0.3466
4 POOR VENOUS ACCESS 2727 0.3406
5 GENERAL SYMPTOM 2216 0.3323
6 OPPORTUNISTIC INFECTION 501 0.3091
7 COLITIS ULCERATIVE 9554 0.2946
8 LOSS OF CONTROL OF LEGS 1046 0.2919
9 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 2057 0.2913
See all enriched reactions for Integrin Receptor Antagonist [EPC]